

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* HANLON SUSAN M _____ (Last) (First) (Middle) 400 WOOD ROAD _____ (Street) BRAINTREE MA 02184 _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol HAEMONETICS CORP [HAE]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) VP Finance		
3. Date of Earliest Transaction (Month/Day/Year) 11/13/2013			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/13/2013		S		1,188	D	\$39.6201	16,905	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Non-Qualified Stock Option (right to buy)	\$25.535							10/24/2008 ⁽¹⁾	10/24/2014	Common Stock	7,138	7,138	D	
Non-Qualified Stock Option (right to buy)	\$26.47							10/27/2010 ⁽¹⁾	10/27/2016	Common Stock	14,690	14,690	D	
Non-Qualified Stock Option (right to buy)	\$27.275							10/22/2009 ⁽¹⁾	10/22/2015	Common Stock	7,206	7,206	D	
Non-Qualified Stock Option (right to buy)	\$27.495							10/27/2011 ⁽¹⁾	10/27/2017	Common Stock	22,348	22,348	D	
Non-Qualified Stock Option (right to buy)	\$30.67							10/25/2012 ⁽¹⁾	10/25/2018	Common Stock	20,726	20,726	D	
Non-Qualified Stock Option (right to buy)	\$39.055							10/24/2013 ⁽¹⁾	10/24/2019	Common Stock	16,882	16,882	D	
Non-Qualified Stock Option (right to buy)	\$41.66							10/23/2014 ⁽¹⁾	10/23/2023	Common Stock	18,456	18,456	D	
Performance Shares	\$0.0							03/31/2017 ⁽²⁾	12/31/2017 ⁽²⁾	Common Stock	12,500	12,500	D	

Explanation of Responses:

1. Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

2. Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Company's stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

By: Alexander Steffan For:
Susan Hanlon

11/14/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.